JAK1 inhibitors have been demonstrated to possess multiple pharmacological effects and have become therapeutic agents for various diseases, including inflammatory bowel disease (55), rheumatoid arthritis (51), autoimmune diseases (56), and various cancers (57). This evidence concerns the gene JAK1 and cancer.